| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8428928 | Best Practice & Research Clinical Haematology | 2018 | 9 Pages |
Abstract
The clinical success achieved using CD19-directed CAR-T cells has stimulated many academic institutions to explore the feasibility of manufacturing these, and other CAR-T cells, in-house. This article reviews the issues that must be addressed in order to achieve this goal. It includes the manufacturing infrastructure, the regulatory environment, practical aspects of production, and the costs involved.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Adrian P. Gee,